International Journal of Hematology

, Volume 75, Issue 4, pp 440–442 | Cite as

Imatinib Mesylate (Gleevec) in the Treatment of 2 Patients with Philadelphia-Positive ALL Relapsing after Allogeneic Stem Cell Transplantation

  • Keiji Sugimoto
  • Michiaki Mikoshiba
  • Kazuteru Ohashi
  • Hideki Akiyama
  • Hisashi Sakamaki
Letter to the Editor
  • 29 Downloads

Keywords

Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia Imatinib Mesylate Allogeneic Stem Cell Transplantation Leukemic Blast 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hoelzer D. Treatment of acute lymphoblastic leukemia.Semin Hematol. 1994;31:1–15.Google Scholar
  2. 2.
    Sierra J, Radich J, Hansen JA, et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.Blood. 1997;90:1410–1414.Google Scholar
  3. 3.
    Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.J Clin Oncol. 1997;15:433–444.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Collins RH, Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia.Bone Marrow Transplant. 2000;26: 511–516.CrossRefPubMedGoogle Scholar
  5. 5.
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.New Engl J Med. 2001;344:1031–1037.CrossRefPubMedGoogle Scholar
  6. 6.
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.New Engl J Med. 2001;344: 1038–1042.CrossRefPubMedGoogle Scholar
  7. 7.
    Ottmann OG, Sawyers CL, Druker BJ, et al. A phase II study to determine the safety and antileukemic effects of STI571 in adult patients with Philadelphia chromosome positive acute leukemias [abstract].Blood. 2000;96:828a.Google Scholar
  8. 8.
    Talpaz M, Sawyers CL, Kantarjian H, et al. Activity of an abl specific tyrosine kinase inhibitor in patients with bcr-abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis [abstract].Proc Am Soc Clin Oncol. 2000;19:4a.Google Scholar
  9. 9.
    Wassman B, Klein SA, Scheuring U, et al. Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell.Bone Marrow Transplant. 2001;28:721–724.CrossRefGoogle Scholar
  10. 10.
    Kono N, Ohashi K, Okuyama Y, et al. Treatment of relapsing Ph+ acute lymphoblastic leukemia with donor leukocyte infusion followed by quantitative monitoring of residual disease.Hematology. 2001;6:261–265.CrossRefGoogle Scholar
  11. 11.
    Tanimoto M, Miyawaki S, Ino T, et al. Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG).Int J Hematol. 1998;68:421–429.CrossRefGoogle Scholar
  12. 12.
    Ueda T, Miyawaki S, Asou N, et al. Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group.Int J Hematol. 1998;68:279–289.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • Keiji Sugimoto
    • 1
  • Michiaki Mikoshiba
    • 1
  • Kazuteru Ohashi
    • 1
  • Hideki Akiyama
    • 1
  • Hisashi Sakamaki
    • 1
  1. 1.Hematology DivisionTokyo Metropolitan Komagome HospitalTokyoJapan

Personalised recommendations